The clinical problem
One patient, three specialties, and a widening care gap.
Heart failure, chronic kidney disease and type-2 diabetes overlap in the same patients — but almost never in the same clinic, record, or medication plan. Renvia exists because that gap is now the single biggest driver of avoidable admissions in the UK.
Fragmented pathways
Cardiology, nephrology and diabetology operate on separate clinics, letters and titration cycles. Patients bounce between them with no shared plan.
Late escalation
By the time weight gain, breathlessness or renal decline reaches an outpatient clinic, decompensation is usually already underway.
Under-titration
Guideline-directed therapy for HFrEF and diabetic kidney disease is under-dosed in real-world practice, largely because monitoring is episodic.
The cost, quantified
Admissions are the symptom. Silos are the disease.
Cardio-renal-metabolic comorbidity now accounts for a disproportionate share of non-elective bed days across NHS trusts. The pattern is consistent: preventable signals were present days — sometimes weeks — before admission, but no one owned the whole picture.
- £2.3bn
- estimated annual NHS cost of avoidable HF admissions
- 40%+
- of T2D patients develop CKD in their lifetime
- 22%
- of HF patients readmitted within 30 days
- 3×
- mortality when cardio-renal-metabolic conditions coexist
The Renvia response
Manage the trio as one clinical entity.
Renvia treats the cardio-renal-metabolic patient as a single pathway with a single owner — a named clinician working with real-time home data, guideline-embedded triggers, and titration support.
See how the pathway works